Cited by 1,860HER2/EGFR in Cancer ResearchGastric Cancer Management and OutcomesLung Cancer Treatments and Mutations

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Vogel, Charles L., Cobleigh, Melody A., Tripathy, Debu, Gutheil, John C., Harris, Lyndsay N., Fehrenbacher, Louis, Slamon, Dennis J., Murphy, Maureen, Novotny, William F., Burchmore, Michael, Shak, Steven, Stewart, Stanford J., Press, Michael·2002·Journal of Clinical Oncology

DOI 10.1200/jco.2002.20.3.719

Open this paper in CoChat — free account

Abstract

PURPOSE: To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS: One hundred fourteen women with HER2-overexpressing metastatic breast cancer were randomized to receive first-line treatment with trastuzumab 4 mg/kg loading dose, followed by 2 mg/kg weekly, or a higher 8 mg/kg loading dose, followed by 4 mg/kg weekly. RESULTS: The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses. Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively. The clinical benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7%, respectively. The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) analysis were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), respectively. Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clinical benefit had not experienced disease progression at follow-up at 12 months or later. The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%). Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require additional intervention after discontinuation of trastuzumab. There was no clear evidence of a dose-response relationship for response, survival, or adverse events. CONCLUSION: Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.

Integrity signals

Registry

Crossref · 10.1200/jco.2002.20.3.719

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Self-citation
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citation
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817
Self-citation
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767
Self-citation
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P. M., Presta, L. G., Gorman, C., Ridgway, J. B., Henner, D. J., Wong, W., Rowland, A. M., Kotts, C. E., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,926
The biology of erbB-2/nue/HER-2 and its role in cancer
Hynes, N. E. (1994) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(94)90012-4 · Cited by 974
The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review
Ravdin, P. M., & Chamness, G. C. (1995) · Gene · doi:10.1016/0378-1119(94)00866-q · Cited by 250
c-erbB-2 oncoprotein expression in primary and advanced breast cancer
Lovekin, C., Ellis, I. O., Locker, A. P., Robertson, J., Bell, J., Nicholson, R., Gullick, W., Elston, C., & Blamey, R. W. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.101 · Cited by 237

Flagged first, then by citations

Show all 9 references

Sorted by citations

Items 201–300 of 1,009

The Role of Cyclin-dependent Kinase Inhibitor p27Kip1 in Anti-HER2 Antibody-induced G1 Cell Cycle Arrest and Tumor Growth Inhibition
Le, X., Claret, F.-X., Lammayot, A., Tian, L., Deshpande, D. M., LaPushin, R., Tari, A. M., & Bast, R. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300848200 · Cited by 151
Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer
Stemmler, H., Kahlert, S., Siekiera, W., Untch, M., Heinrich, B., & Heinemann, V. (2005) · The Breast · doi:10.1016/j.breast.2005.04.017 · Cited by 150
Impact of Single-chain Fv Antibody Fragment Affinity on Nanoparticle Targeting of Epidermal Growth Factor Receptor-expressing Tumor Cells
Zhou, Y., Drummond, D. C., Zou, H., Hayes, M. E., Adams, G. P., Kirpotin, D. B., & Marks, J. D. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.011 · Cited by 151
Comparison of HER-2 and Hormone Receptor Expression in Primary Breast Cancers and Asynchronous Paired Metastases: Impact on Patient Management
Guarneri, V., Giovannelli, S., Ficarra, G., Bettelli, S. R., Maiorana, A., Piacentini, F., Barbieri, E., Dieci, M. V., D’Amico, R., Jovic, G., et al. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0048 · Cited by 150
Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications
Montemurro, F., Cosimo, S. D., & Arpino, G. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt287 · Cited by 145
Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma
Lassus, H. J., Sihto, H. J., Leminen, A., Joensuu, H., Isola, J. J., Nupponen, N. N., & Bützow, R. C. (2006) · Journal of Molecular Medicine · doi:10.1007/s00109-006-0054-4 · Cited by 146
The use of RNA-based treatments in the field of cancer immunotherapy
Chehelgerdi, M., & Chehelgerdi, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01807-w · Cited by 149
Cross-Talk Between the ErbB/HER Family and the Type I Insulin-Like Growth Factor Receptor Signaling Pathway in Breast Cancer
Jin, Q., & Esteva, F. J. (2008) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-008-9107-3 · Cited by 143
Monitoring of Serum Her-2/ neu Predicts Response and Progression-Free Survival to Trastuzumab-Based Treatment in Patients with Metastatic Breast Cancer
Köstler, W. J., Schwab, B., Singer, C. F., Neumann, R., Rücklinger, E., Brodowicz, T., Tomek, S., Niedermayr, M., Hejna, M., Steger, G. G., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0385-3 · Cited by 143
Intratumoral Delivery of IL-21 Overcomes Anti-Her2/Neu Resistance through Shifting Tumor-Associated Macrophages from M2 to M1 Phenotype
Xu, M. M., Liu, M., Du, X., Li, S., Li, H., Li, X., Li, Y., Wang, Y., Qin, Z., Fu, Y., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402603 · Cited by 146
Cardiac Management during Adjuvant Trastuzumab Therapy: Recommendations of the Canadian Trastuzumab Working Group
Mackey, J. R., Clemons, M. J., Côté, M. A., Delgado, D., Dent, S. F., Paterson, A., Provencher, L., Sawyer, M. B., & Verma, S. (2008) · Current Oncology · doi:10.3747/co.2008.199 · Cited by 142
Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2+ Metastatic Breast Cancer
Jahanzeb, M., Mortimer, J. E., Yunus, F., Irwin, D. H., Speyer, J. L., Koletsky, A. J., Klein, P., Sabir, T., & Kronish, L. E. (2002) · The Oncologist · doi:10.1634/theoncologist.7-5-410 · Cited by 142
Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancer
Guan, Z., Xu, B., DeSilvio, M., Shen, Z., Arpornwirat, W., Tong, Z., Lorvidhaya, V., Jiang, Z., Yang, J., Makhson, A. N., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.5241 · Cited by 141
Emerging Technologies for Assessing HER2 Amplification
Penault-Llorca, F. M., Bilous, M., Dowsett, M., Hanna, W. M., OSAMURA, R. Y., Rüschoff, J., & van de Vijver, M. J. (2009) · American Journal of Clinical Pathology · doi:10.1309/ajcpv2i0hgpmgbsq · Cited by 139
HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials
Press, M. F., Sauter, G., Buyse, M. E., Fourmanoir, H., Quinaux, E., Tsao-Wei, D. D., EIERMANN, W., Robert, N. J., Pieńkowski, T., Crown, J. P., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.6693 · Cited by 142
Self-citation
Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations
Martín, M., Esteva, F. J., Alba, E., Khandheria, B. K., de Isla, L. P., García-Sáenz, J. Á., Márquez, A., Sengupta, P. P., & Zamorano, J. L. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0137 · Cited by 141
HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer
Lee, H. J., Seo, A. N., Kim, E. J., Jang, M. H., Suh, K. J., Ryu, H. S., Kim, Y. J., Kim, J. H., Im, S., Gong, G., et al. (2014) · American Journal of Clinical Pathology · doi:10.1309/ajcpirl4guvgk3yx · Cited by 137
Development of Herceptin resistance in breast cancer cells
Kute, T. E., Läck, C. M., Willingham, M. C., Bishwokama, B., Williams, H. C., Barrett, K., Mitchell, T., & Vaughn, J. P. (2003) · Cytometry Part A · doi:10.1002/cyto.a.10095 · Cited by 136
PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab
Jensen, J. D., Knoop, A. S., Lænkholm, A., Grauslund, M., Jensen, M., Santoni‐Rugiu, E., Andersson, M., & Ewertz, M. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr546 · Cited by 135
Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence
Pandya, K., Meeke, K., Clementz, A. G., Rogowski, A., Roberts, J., Miele, L., Albain, K. S., & Osipo, C. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.321 · Cited by 135
Standardization of HER2 testing: results of an international proficiency-testing ring study
Dowsett, M., Hanna, W. M., Kockx, M. M., Penault-Llorca, F. M., Rüschoff, J., Gutjahr, T., Habben, K., & van de Vijver, M. J. (2007) · Modern Pathology · doi:10.1038/modpathol.3800774 · Cited by 134
Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers
Letessier, A., Sircoulomb, F., Ginestier, C., Cervera, N., Monville, F., Gelsi‐Boyer, V., Esterni, B., Geneix, J., Finetti, P., Zemmour, C., et al. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-245 · Cited by 134
Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
Saura, C., Bendell, J. C., Jérusalem, G., Su, S., Ru, Q. C., Buck, S., Mills, D., Ruquet, S., Bosch, A., Urruticoechea, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1070 · Cited by 137
Trastuzumab cardiotoxicity: from clinical trials to experimental studies
Németh, B. T., Varga, Z. V., Wu, W. J., & Pacher, P. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13643 · Cited by 133
Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary
Kato, S., Krishnamurthy, N., Banks, K. C., De, P. K., Williams, K. A., Williams, C. B., Leyland-Jones, B. R., Lippman, S. M., Lanman, R. B., & Kurzrock, R. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0628 · Cited by 134
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial
Safran, H. P., Winter, K., Ilson, D. H., Wigle, D. A., DiPetrillo, T., Haddock, M. G., Hong, T. S., Leichman, L. P., Rajdev, L., Resnick, M., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00718-x · Cited by 138
Use of CA-125 in Clinical Trial Evaluation of New Therapeutic Drugs for Ovarian Cancer
Rustin, G. J. S., Bast, R. C., Kelloff, G. J., Barrett, J. C., Carter, S. K., Nisen, P. D., Sigman, C. C., Parkinson, D. R., & Ruddon, R. W. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0787 · Cited by 133
HER2-positive breast cancer: Current and new therapeutic strategies
Escrivá-de-Romaní, S., Arumí, M., Bellet, M., & Saura, C. (2018) · The Breast · doi:10.1016/j.breast.2018.03.006 · Cited by 132
HER2-Positive Breast Cancer
Engel, R. H., & Kaklamani, V. (2007) · Drugs · doi:10.2165/00003495-200767090-00006 · Cited by 129
Silencing the MET oncogene leads to regression of experimental tumors and metastases
Corso, S., Migliore, C., Ghiso, E., Rosa, G. D., Comoglio, P. M., & Giordano, S. (2007) · Oncogene · doi:10.1038/sj.onc.1210697 · Cited by 129
Cardiac profiles of liposomal anthracyclines
Theodoulou, M., & Hudis, C. A. (2004) · Cancer · doi:10.1002/cncr.20207 · Cited by 130
TGFα expression impairs Trastuzumab-induced HER2 downregulation
Valabrega, G., Montemurro, F., Sarotto, I., Petrelli, A., Rubini, P., Tacchetti, C., Aglietta, M., Comoglio, P. M., & Giordano, S. (2005) · Oncogene · doi:10.1038/sj.onc.1208478 · Cited by 129
Advances in Targeting Human Epidermal Growth Factor Receptor-2 Signaling for Cancer Therapy
Meric‐Bernstam, F., & Hung, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1732 · Cited by 129
A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects
Strome, S. E., Sausville, E. A., & Mann, D. L. (2007) · The Oncologist · doi:10.1634/theoncologist.12-9-1084 · Cited by 133
Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2‐Positive Breast Cancer
Wynne, C., Harvey, V. J., Schwabe, C., Waaka, D., McIntyre, C., & Bittner, B. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270012436560 · Cited by 127
Human cancers converge at the HIF-2α oncogenic axis
Franovic, A., Holterman, C. E., Payette, J., & Lee, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906432106 · Cited by 134
Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era
Olson, E. M., Najita, J., Sohl, J. J., Arnaout, A., Burstein, H. J., Winer, E. P., & Lin, N. (2013) · The Breast · doi:10.1016/j.breast.2012.12.006 · Cited by 128
Trastuzumab Administration Can Effectively Target Chemotherapy-Resistant Cytokeratin-19 Messenger RNA–Positive Tumor Cells in the Peripheral Blood and Bone Marrow of Patients With Breast Cancer
Bozionellou, V., Mavroudis, D., Perraki, M., Papadopoulos, S., Apostolaki, S., Stathopoulos, E. N., Stathopoulou, A., Lianidou, E. S., & Georgoulias, V. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0094 · Cited by 128
Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer
Minuti, G., Cappuzzo, F., Duchnowska, R., Jassem, J., Fabi, A., O’Brien, T., Mendoza, A. D., Landi, L., Biernat, W., Czartoryska-Arłukowicz, B., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.335 · Cited by 127
HER2 overexpression correlates with survival after curative resection of pancreatic cancer
Komoto, M., Nakata, B., Amano, R., Yamada, N., Yashiro, M., Ohira, M., Wakasa, K., & Hirakawa, K. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01176.x · Cited by 126
Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition
Huang, D., Duan, H., Huang, H., Tong, X., Han, Y. K., Ru, G., Qu, L., Shou, C., & Zhao, Z. (2016) · Scientific Reports · doi:10.1038/srep20502 · Cited by 126
Trastuzumab
Plosker, G. L., & Keam, S. J. (2006) · Drugs · doi:10.2165/00003495-200666040-00005 · Cited by 127
Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis
Dendukuri, N., Khetani, K., McIsaac, M., & Brophy, J. M. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.061011 · Cited by 125
Outcome of Patients with HER2-Positive Advanced Breast Cancer Progressing During Trastuzumab-Based Therapy
Montemurro, F., Donadio, M., Clavarezza, M., Redana, S., Jacomuzzi, M. E., Valabrega, G., Danese, S., Vietti-Ramus, G., Durando, A., Venturini, M., et al. (2006) · The Oncologist · doi:10.1634/theoncologist.11-4-318 · Cited by 123
Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin
Wang, S., Huang, X., Lee, C., & Liu, B. (2010) · Oncogene · doi:10.1038/onc.2010.180 · Cited by 126
Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts
McLarty, K., Cornelissen, B. T., Scollard, D. A., Done, S. J., Chun, K., & Reilly, R. M. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0923-x · Cited by 124
Profiling of the cell surface proteome
Jang, J. H., & Hanash, S. (2003) · PROTEOMICS · doi:10.1002/pmic.200300563 · Cited by 123
Epigenetics in Breast and Prostate Cancer
Wu, Y., Sarkissyan, M., & Vadgama, J. V. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-1804-1_23 · Cited by 128
Genomic and proteomic biomarkers for cancer: A multitude of opportunities
Tainsky, M. A. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.04.004 · Cited by 124
Selective Inhibition of ErbB2-Overexpressing Breast Cancer In vivo by a Novel TAT-Based ErbB2-Targeting Signal Transducers and Activators of Transcription 3–Blocking Peptide
Tan, M., Lan, K., Yao, J., Lu, C., Sun, M., Neal, C. L., Lü, J., & Yu, D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2747 · Cited by 123
Interplay between tumor microenvironment and partial EMT as the driver of tumor progression
Aggarwal, V., Montoya, C. A., Donnenberg, V. S., & Sant, S. (2021) · iScience · doi:10.1016/j.isci.2021.102113 · Cited by 125
Comparison of HER2 status between primary tumor and disseminated tumor cells in␣primary breast cancer patients
Solomayer, E. F., Becker, S., Becker‐Pergola, G., Bachmann, R., Krämer, B., Vogel, U. F., Neubauer, H. J., Wallwiener, D. R., Huober, J., & Fehm, T. N. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9147-y · Cited by 122
Vorinostat (SAHA) and Breast Cancer: An Overview
Wawruszak, A., Borkiewicz, L., Okoń, E., Kukuła‐Koch, W., Afshan, S., & Hałasa, M. (2021) · Cancers · doi:10.3390/cancers13184700 · Cited by 124
Prognostic significance of phosphorylated P38 mitogen‐activated protein kinase and HER‐2 expression in lymph node‐positive breast carcinoma
Esteva, F. J., Şahin, A. A., Smith, T. L., Yang, Y., Pusztai, L., Nahta, R., Buchholz, T. A., Buzdar, A. U., Hortobágyi, G. N., & Bacus, S. S. (2004) · Cancer · doi:10.1002/cncr.11940 · Cited by 121
Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer
Park, I. H., Ro, J., Lee, K. S., Nam, B., Kwon, Y., & Shin, K. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn539 · Cited by 121
Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping
Wulfkuhle, J. D., Berg, D., Wolff, C., Langer, R., Tran, K., Illi, J., Espina, V. A., Pierobon, M., Deng, J., DeMichele, A. M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0452 · Cited by 122
Determining True HER2 Gene Status in Breast Cancers With Polysomy by Using Alternative Chromosome 17 Reference Genes: Implications for Anti-HER2 Targeted Therapy
Tse, C. H., Hwang, H. C., Goldstein, L. C., Kandalaft, P. L., Wiley, J. C., Kussick, S. J., & Gown, A. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.0107 · Cited by 119
Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy
Derakhshani, A., Rezaei, Z., Safarpour, H., Sabri, M., Mir, A., Sanati, M. A., Vahidian, F., Moghadam, A. G., Aghadoukht, A., Hajiasgharzadeh, K., et al. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29216 · Cited by 128
Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice
Jumbe, N. L., Xin, Y., Leipold, D. D., Crocker, L., Dugger, D., Mai, E., Sliwkowski, M. X., Fielder, P. J., & Tibbitts, J. (2010) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-010-9156-2 · Cited by 119
Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
O’Brien, N. A., McDonald, K., Luo, T., von Euw, E., Kalous, O., Conklin, D. F., Hurvitz, S. A., di Tomaso, E., Schnell, C., Linnartz, R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2769 · Cited by 122
Self-citation
CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1‐ErbB‐PI3K signaling
Choi, H., Jin, S., Cho, H., Won, H., An, H. W., Jeong, G., Park, Y., Kim, H.-Y., Park, M. K., Son, T., et al. (2019) · EMBO Reports · doi:10.15252/embr.201948058 · Cited by 120
The Influence of Polysomy 17 on HER2 Gene and Protein Expression in Adenocarcinoma of the Breast
Downs-Kelly, E. P., Yoder, B. J., Stoler, M. H., Tubbs, R. R., Skacel, M., Grogan, T. M., Roche, P. C., & Hicks, D. G. (2005) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000165528.78945.95 · Cited by 119
Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patients
Ramaswamy, B., ELIAS, A. D., Kelbick, N., Dodley, A., Morrow, M., Hauger, M., Allen, J., Rhoades, C. A., Kendra, K. L., Chen, H. X., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2603 · Cited by 119
Heart Failure Induced by Non-Cardiac Drugs
rdal, L. S., & Spigset, O. (2006) · Drug Safety · doi:10.2165/00002018-200629070-00003 · Cited by 119
HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques
Ellis, C. M., Dyson, M. J., Stephenson, T. J., & Maltby, E. L. (2005) · Journal of Clinical Pathology · doi:10.1136/jcp.2004.023424 · Cited by 118
HER2 and Breast Cancer Stem Cells: More than Meets the Eye
Körkaya, H., & Wicha, M. S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0260 · Cited by 120
Thirty Years of HER3: From Basic Biology to Therapeutic Interventions
Haikala, H. M., & Janne, P. A. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4465 · Cited by 117
Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer
Arnould, L., Denoux, Y., MacGrogan, G. M., Penault-Llorca, F. M., Fiche, M., Treilleux, I., Mathieu, M. C., Vincent‐Salomon, A., Vilain, M. O., & Couturier, J. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600943 · Cited by 117
Nonendocrine Pathways and Endocrine Resistance
Nicholson, R. I., Hutcheson, I. R., Knowlden, J. M., Jones, H., Harper, M. E., Jordan, N., Hiscox, S., Barrow, D., & Gee, J. M. W. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-031206 · Cited by 117
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
ElSahwi, K. S., Bellone, S., Cocco, E., Cargnelutti, M., Casagrande, F., Bellone, M., Abu-Khalaf, M., Buza, N., Tavassoli, F. A., Hui, P., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605448 · Cited by 116
Bispecific Minibodies Targeting HER2/neu and CD16 Exhibit Improved Tumor Lysis When Placed in a Divalent Tumor Antigen Binding Format
Shahied, L., Tang, Y., Alpaugh, R. K., Somer, R. A., Greenspon, D., & Weiner, L. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407888200 · Cited by 120
Even Low-level HER2 Expression May be Associated With Worse Outcome in Node-positive Breast Cancer
Gilcrease, M. Z., Woodward, W. A., Nicolas, M. M., Corley, L. J., Fuller, G. N., Esteva, F. J., Tucker, S. L., & Buchholz, T. A. (2009) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31819437f9 · Cited by 115
A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study
Wiedermann, U., Wiltschke, C., Jasińska, J., Kundi, M., Zurbriggen, R., Garner‐Spitzer, E., Bartsch, R., Steger, G. G., Pehamberger, H., Scheiner, O., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0666-9 · Cited by 115
Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers
Harandi, A., Zaidi, A., Stocker, A. M., & Laber, D. A. (2009) · Journal of Oncology · doi:10.1155/2009/567486 · Cited by 116
Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb‐B2
Clamon, G. H., Herndon, J. E., Kern, J. A., Govindan, R., Garst, J. L., Watson, D. M., & Green, M. (2005) · Cancer · doi:10.1002/cncr.20950 · Cited by 115
Growth Factor Receptors in Breast Cancer: Potential for Therapeutic Intervention
Nahta, R., Hortobágyi, G. N., & Esteva, F. J. (2003) · The Oncologist · doi:10.1634/theoncologist.8-1-5 · Cited by 116
The Impact of HER2/neuExpression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Benavides, L. C., Gates, J. D., Carmichael, M. G., Patel, R. S., Holmes, J. P., Hueman, M. T., Mittendorf, E. A., Craig, D., Stojadinovic, A., Ponniah, S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1126 · Cited by 115
Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells
Carpin, L. B., Bickford, L. R., Agollah, G. D., Yu, T.-K., Schiff, R., Li, Y., & Drezek, R. A. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0811-5 · Cited by 114
HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment
Sitia, L., Sevieri, M., Signati, L., Bonizzi, A., Chesi, A., Mainini, F., Corsi, F., & Mazzucchelli, S. (2022) · Cancers · doi:10.3390/cancers14102424 · Cited by 122
Mechanisms of resistance to anti‐human epidermal growth factor receptor 2 agents in breast cancer
Mukohara, T. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01711.x · Cited by 113
Determination of HER-2 Status and Chromosome 17 Polysomy in Breast Carcinomas Comparing HercepTest and PathVysion FISH Assay
Varshney, D., Zhou, Y. Y., Geller, S. A., & Alsabeh, R. (2004) · American Journal of Clinical Pathology · doi:10.1309/fuqh-92b0-3902-5lhg · Cited by 114
Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer
Gavin, P. G., Song, N., Kim, S. R., Lipchik, C., Johnson, N. L., Bandos, H., Finnigan, M., Rastogi, P., Fehrenbacher, L., Mamounas, E. P., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4884 · Cited by 115
Self-citation
NK Cell-Based Immunotherapy in Cancer Metastasis
Lorenzo‐Herrero, S., López‐Soto, A., Sordo‐Bahamonde, C., González, A. P., Vitale, M., & Gonzalez, S. R. (2018) · Cancers · doi:10.3390/cancers11010029 · Cited by 114
Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors
Chen, F. L., Xia, W., & Spector, N. L. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0581 · Cited by 114
PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling
Moody, S. E., Schinzel, A. C., Singh, S., Izzo, F., Strickland, M. R., Luo, L. Y., Thomas, S. R., Boehm, J. S., Kim, S. Y., Wang, Z. C., et al. (2014) · Oncogene · doi:10.1038/onc.2014.153 · Cited by 110
Targeted therapies: how personal should we go?
Martini, M., Vecchione, L., Siena, S., Tejpar, S., & Bardelli, A. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.164 · Cited by 112
Building a Personalized Medicine Infrastructure at a Major Cancer Center
Meric‐Bernstam, F., Farhangfar, C. J., Mendelsohn, J. M., & Mills, G. B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3043 · Cited by 112
Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
Keung, M. Y., Wu, Y., Badar, F., & Vadgama, J. V. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040940 · Cited by 115
HER-2/neu overexpression is an independent prognostic factor in colorectal cancer
Park, D. I., Kang, M.-S., Oh, S. J., Kim, H. J., Cho, Y. K., Sohn, C. I., Jeon, W. K., Kim, B. I., Han, W. K., Kim, H., et al. (2006) · International Journal of Colorectal Disease · doi:10.1007/s00384-006-0192-8 · Cited by 112
Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248
Potapova, O., Laird, A., Nannini, M., Barone, A., Li, G., Moss, K. G., Cherrington, J. M., & Mendel, D. B. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-03-0156 · Cited by 111
A Phase I Study of Interleukin 12 with Trastuzumab in Patients with Human Epidermal Growth Factor Receptor-2-Overexpressing Malignancies
Parihar, R., Nadella, P. C., Lewis, A., Jensen, R. R., Hoff, C. D., Dierksheide, J. E., VanBuskirk, A. M., MAGRO, C. M. J., Young, D. C., Shapiro, C. L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0265 · Cited by 111
Neuregulins and Cancer
Montero, J. C., Barrueco, R. R., Ocaña, A., Dı́az-Rodrı́guez, E., Esparı́s-Ogando, A., & Pandiella, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5133 · Cited by 111
Breast Cancer Classification in Ultrasound Images using Transfer Learning
Hijab, A., Rushdi, M. A., Gomaa, M. M. M., & Eldeib, A. (2019) · International Conference on Advances in Biomedical Engineering (ICABME) · doi:10.1109/icabme47164.2019.8940291 · Cited by 110
A Nonfucosylated Anti-HER2 Antibody Augments Antibody-Dependent Cellular Cytotoxicity in Breast Cancer Patients
Suzuki, E., Niwa, R., Saji, S., Muta, M., Hirose, M., Iida, S., Shiotsu, Y., Satoh, M., Shitara, K., Kondo, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1335 · Cited by 111
Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial
Lum, L. G., Thakur, A. B., Al-Kadhimi, Z. S., Colvin, G. A., Cummings, F. J., Legare, R. D., Dizon, D. S., KOUTTAB, N. M., Maizel, A., Colaiace, W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2280 · Cited by 109
Mediterranean diet, olive oil and cancer
Colomer, R., & Menéndez, J. A. (2006) · Clinical & Translational Oncology · doi:10.1007/s12094-006-0090-0 · Cited by 109
Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors?
Leibl, S., & Moinfar, F. (2005) · Journal of Clinical Pathology · doi:10.1136/jcp.2004.025163 · Cited by 109
Human epidermal growth factor receptor-2-positive breast cancer: current management of early, advanced, and recurrent disease
Callahan, R. D., & Hurvitz, S. A. (2010) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e3283414e87 · Cited by 108
Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a Tertiary Care Facility Increases HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Concordance and Decreases the Number of Inconclusive Cases
Middleton, L. P., Price, K. M., Puig, P., Heydon, L. J., Tarco, E., Sneige, N., Barr, K., & Deavers, M. T. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.5.775 · Cited by 108
Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer
O’Brien, N. A., Conklin, D. F., Beckmann, R. P., Luo, T., Chau, K., Thomas, J. D., Nulty, A. M., Marchal, C. C., Kalous, O., von Euw, E., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0290 · Cited by 108
Self-citation

Authors: Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., Shak, S., Stewart, S. J., & Press, M.
Affiliations: University of Southern California (US)
ORCID: Cobleigh, Melody A.
Tripathy, Debu
Harris, Lyndsay N.
Fehrenbacher, Louis
Slamon, Dennis J.
Novotny, William F.
Shak, Steven
Press, Michael
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2002-02-01
Volume: 20
Issue: 3
Pages: 719-726
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2002.20.3.719
OpenAlex: W4239989216
Cited by: 1,860
References: 9
Citations by year: 2026: 12 · 2025: 34 · 2024: 52 · 2023: 75 · 2022: 113 · 2021: 67 · 2020: 72 · 2019: 62 · 2018: 97 · 2017: 95 · 2016: 87 · 2015: 88 · 2014: 71 · 2013: 91 · 2012: 74
FWCI: 32.63
Type: journal article
Language: en
Update notices: new_edition (2023-03-15)
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
Funders: National Cancer Institute (CA48780)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords: trastuzumab, HER2-positive breast cancer, metastatic breast cancer, first-line therapy, single-agent chemotherapy, HER2 immunohistochemistry, HER2 amplification, objective response rate, adverse cardiac events, dose-response relationship, treatment safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks